Close Menu

NEW YORK – Bristol Myers Squibb and Bluebird Bio said on Wednesday that they submitted a biologics license application to the US Food and Drug Administration for their B-cell maturation antigen-directed CAR T-cell immunotherapy idecabtagene vicleucel.

The therapy is being developed as a treatment for adult patients with relapsed or refractory multiple myeloma, a cancer that occurs in the plasma cells.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.